Better Pharma Stock: GlaxoSmithKline vs. Bristol-Myers Squibb

·3-min read
Better Pharma Stock: GlaxoSmithKline vs. Bristol-Myers Squibb

In particular, GlaxoSmithKline (NYSE: GSK) and Bristol-Myers Squibb (NYSE: BMY) are two of the world's most preeminent pharmaceutical companies, but neither has consistently outperformed the market over the past five years. Right now, Bristol-Myers is in the doldrums. Over the past three years, its quarterly revenue has jumped 94.6% and quarterly net income has risen 33.3%.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting